See the DrugPatentWatch profile for sarclisa
Sarclisa, also known as isatuximab, is a monoclonal antibody used to treat multiple myeloma, a type of blood cancer. The techniques used to create Sarclisa's antibody involve the use of hybridoma technology and recombinant DNA technology.
Hybridoma technology is a method used to produce monoclonal antibodies, which are identical immune cells that are clones of a unique parent cell. This technology involves the fusion of B cells, which produce antibodies, with myeloma cells, which are cancerous cells that can replicate indefinitely. The resulting hybrid cells, called hybridomas, can produce a large quantity of a single type of antibody that can bind to a specific antigen. In the case of Sarclisa, the antibody produced by the hybridomas binds to a specific antigen found on the surface of multiple myeloma cells [1].
Recombinant DNA technology is another technique used in the creation of Sarclisa's antibody. This technology involves the manipulation of DNA molecules to create new combinations of genetic material. In the case of Sarclisa, recombinant DNA technology was used to modify the genetic material of the hybridomas to produce a antibody with specific properties. Specifically, the genetic material of the hybridomas was modified to encode for an antibody that binds to the CD38 antigen found on the surface of multiple myeloma cells [1].
It is worth noting that the use of these techniques in the creation of Sarclisa's antibody has allowed for the development of a targeted therapy for multiple myeloma. Sarclisa works by binding to the CD38 antigen on the surface of multiple myeloma cells, which triggers a series of events that ultimately leads to the death of the cancer cells [1].
In summary, the techniques used to create Sarclisa's antibody involve the use of hybridoma technology and recombinant DNA technology. Hybridoma technology was used to produce monoclonal antibodies that bind to a specific antigen found on multiple myeloma cells, while recombinant DNA technology was used to modify the genetic material of the hybridomas to produce an antibody with specific properties.
Sources:
[1] DrugPatentWatch.com. (n.d.). Isatuximab. Retrieved from <
https://www.drugpatentwatch.com/drugs/isatuximab>